|
1. Biologie
|
|
|
CRISPR hits a snag: Our immune systems may attack the treatment [STAT]
|
|
|
|
|
|
But
researchers not involved with the study said its findings, if
substantiated, could be worked around. Many of the first planned CRISPR
clinical trials, for example, involve removing cells from patients,
fixing their DNA, and then returning them to patients. In that case,
it’s possible that there will be few or no CRISPR proteins remaining for
the immune system to detect.
|
|
|
|
|
|
|
|
2. Etiologie
|
|
|
|
3.1 Prévention - Tabac
|
|
|
Drugs, gums or patches won’t increase your chances of quitting [The Conversation]
|
|
|
|
|
|
The
US researchers followed two groups of people 2002/03 and 2010/11 and
found at the end of the 12-month period, those using varenicline (sold
in Australia as Champix), bupropion (Zyban), or nicotine-replacement
therapy (gums, mints or patches) were no more likely to have quit
smoking for 30 days or more than those who didn’t use these drugs.
|
|
|
|
|
|
|
|
4. Dépistage, diagnostic et pronostic
|
|
|
|
4.12 Biopsies liquides
|
|
|
|
4.2 Dép., diag. & prono. - Génome
|
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
|
5. Traitements
|
|
|
|
5.12 Immunothérapies
|
|
|
Cracking Tumor Defiance [Harvard Medical School]
|
|
|
|
|
|
Two
research groups from Harvard Medical School based at Dana-Farber Cancer
Institute have independently discovered a genetic mechanism in cancer
cells that influences whether they resist or respond to immunotherapy
drugs known as checkpoint inhibitors.
|
|
|
|
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.5 Immunothérapies - Pharma
|
|
|
|
5.2.1 Pharma - Partenariats
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
|
5.9.4 AACR - poumon
|
|
|
|
6. Lutte contre les cancers
|
|
|